Unmet Clinical Needs


  • 6.35 million newly diagnosed cancer patients receive radiation therapy each year5
  • Over 1 million of the 6.35 million cancer patients are in the United States5
  • It is estimated that each cancer patient receives 15-35 radiation therapy sessions during their course of treatment5
  • Annually in the United States $2 billion is billed for in-patient medical costs related to radiation therapy skin complications6,7
  • Every 2 minutes, a woman in the United States is diagnosed with breast cancer8


5Paravati, Anthony et al. “Variation in the Cost of Radiation Therapy Among Medicare Patients with Cancer.” J of Oncology Practice. 5 (2015): 403-409

6"The Web's Free ICD-9-CM Medical Coding Reference." ICD9data.com ICD9Data, Web. 28 September 2017

7"Healthcare Cost and Utilization Project (HCUP).” Ahrq.gov.com. Agency for Healthcare Research and Quality, July 2017. Web. 28 September 2017

8“Breast Cancer Fact Sheet” Komen.org. Susan G. Komen October 2017

_More Facts_


  • Globally, approximately 6 million out of the estimated 18 million newly diagnosed patients with cancer will receive radiation therapy each year and 1 million of them live in the United States.5,6
  • BioCurity's technology and drug candidates have the potential to significantly reduce radiation toxicity not just for these newly diagnosed cancer patients but also for the many other cancer patients who receive radiation as part of their ongoing treatment for cancer.
  • Some of the adverse side effects of radiation treatment include skin burns, blistering, permanent scarring and damage to internal non-cancer healthy tissue. The medical care for these side effects is estimated at $3 billion annually in the United States.7,8
  • Physicians, patients, nonprofit organizations, hospitals, insurance companies and advocates of cancer patient support programs understand the economic costs and severe toll this damage to healthy tissue inflicts on patients already struggling to fight their cancer.
  • BioCurity's proprietary technology is designed to prevent or mitigate damage to the skin and internal tissue during radiation therapy, without impairing the effectiveness of radiation treatment on the patient's cancer cells. The proposed drugs generated from BioCurity's technology have been preclinically tested for multiple cancers including breast, lung, head & neck, prostate and colorectal cancer. The delivery system of the proposed drugs are topical to prevent or mitigate radiation damage to the skin (radiation dermatitis) and an IV (intravenous) for the internal tissue.


1Ryan, Julie. “Ionizing Radiation: The Good, the Bad, and the Ugly.” J Invest Dermatol. 132 (2012): 985-993

2Bray, Fleta, et al. “Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.” Dermatol Ther. 6 (2016): 185-206

3Radvansky, Lauren, et al. “Prevention and Management of Radiation-Induced Dermatitis, Mucositis and Xerostomia.” Am J Health Syst Pharm. 12 (2013): 1025-1032

4Peach, Matthew, et al. “Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer.” Prostate Cancer. 15 (2015): 1-11

5IAEA Reports 2017, Radiotherapy in Cancer Care, Facing the Global Challenge

6"All Cancers. Source Globcan: 2018." International Agency for Research on Cancer. March 2019. Web 23. August 2019

7"The Web's Free ICD-9-CM Medical Coding Reference.” ICD9data.com. ICD9Data, Web. 28 September 2018.

8“Healthcare Cost and Utilization Project (HCUP).” Ahrq.gov.com. Agency for Healthcare Research and Quality, July 2017.  Web. 28 September 2018.

Print Print | Sitemap
© 2020 BioCurity Pharmaceuticals, Inc. All Rights Reserved.